Answers are grounded in this paper and cite their sources.
High quality data showing bioequivalence and clinical efficacy of generic immunosuppressive drugs in patients with transplants are lacking. Given the serious consequences of rejection and allograft failure, well designed studies on bioequivalence and safety of generic immunosuppression in transplant recipients are needed.
No takes yet. Share an insight, caveat, or question.
Molnar et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: